Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CV9201 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CV9201 | EXPERIMENTAL | CV9201 is composed of five formulated mRNAs (drug product components) encoding antigens that are overexpressed or exclusively expressed in NSCLC cells. |
| Name | Type | Description |
|---|---|---|
| CV9201 | BIOLOGICAL | CV9201 is a vaccine consisting of five drug product components. Treatment will be administered on 5 timepoints. |
Inclusion Criteria: 1. Male or female and age ≥ 18 yrs and ≤ 75 2. Histologically or cytologically confirmed and documented stage IIIB /IV NSCLC 3. Documented stable disease or objective response according to RECIST criteria after initial chemotherapy or chemo-radiotherapy for advanced, unresectabl...
Top 20 of 84 competitors
CV9201 is an investigational cancer vaccine being studied for the treatment of Non Small Cell Lung Cancer (NSCLC). It is designed to be used in patients with stage IIIB/IV disease, as evaluated in a completed Phase 1 clinical trial.
CV9201 is being developed by BioNTech SE, a biotechnology company traded on the NASDAQ under the ticker symbol BNTX. The company is conducting clinical research on this investigational cancer vaccine for Non Small Cell Lung Cancer.
CV9201 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational, meaning it has not been approved by regulatory authorities and is still undergoing clinical evaluation.
CV9201 has been studied in one completed Phase 1 clinical trial with the identifier NCT00923312. This trial enrolled 46 participants with stage IIIB/IV Non Small Cell Lung Cancer and was conducted in Germany and Switzerland.
CV9201 is classified as a monoclonal antibody modality, though it is described as a cancer vaccine in its clinical trial. It is being investigated for its potential role in treating Non Small Cell Lung Cancer.
The completed Phase 1 clinical trial of CV9201 was not randomized and was not double-blinded. It was an uncontrolled study, meaning there was no control group, and all enrolled participants received the investigational treatment.